PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER Drug Patent Profile

« Back to Dashboard

When do Piperacillin And Tazobactam And Sodium Chloride In Duplex Container patents expire, and when can generic versions of Piperacillin And Tazobactam And Sodium Chloride In Duplex Container launch?

Piperacillin And Tazobactam And Sodium Chloride In Duplex Container is a drug marketed by B Braun Medical and is included in one NDA.

The generic ingredient in PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER is piperacillin sodium; tazobactam sodium. There is one drug master file entry for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the piperacillin sodium; tazobactam sodium profile page.

Summary for PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
DailyMed Link:	PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER at DailyMed

Pharmacology for PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER

Drug Class	Penicillin-class Antibacterial beta Lactamase Inhibitor
Mechanism of Action	beta Lactamase Inhibitors

US Patents and Regulatory Information for PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
B Braun Medical	PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER	piperacillin sodium; tazobactam sodium	POWDER;INTRAVENOUS	206056-001	Apr 3, 2025		RX	Yes	Yes
B Braun Medical	PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER	piperacillin sodium; tazobactam sodium	POWDER;INTRAVENOUS	206056-002	Apr 3, 2025		RX	Yes	Yes
B Braun Medical	PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER	piperacillin sodium; tazobactam sodium	POWDER;INTRAVENOUS	206056-003	Apr 3, 2025		RX	Yes	Yes

Piperacillin and Tazobactam in Sodium Chloride DUPLEX Container: Market Dynamics, Patent Status, and Financial Outlook

Last updated: September 9, 2026

Piperacillin and tazobactam in 0.9% sodium chloride in the DUPLEX container is a premixed hospital injectable antibiotic used for serious bacterial infections. The product competes in a mature, largely generic market where purchasing contracts, manufacturing reliability, drug shortages, and hospital formulary position matter more than patent exclusivity.

B. Braun Medical is associated with the DUPLEX dual-chamber container platform. The product’s revenue is not separately disclosed, and its financial trajectory is best assessed through hospital injectable demand, generic price erosion, supply continuity, and the value of premixed delivery technology rather than through branded-drug metrics.

What is piperacillin and tazobactam in a DUPLEX container?

The product combines piperacillin, an extended-spectrum penicillin antibiotic, with tazobactam, a beta-lactamase inhibitor. Sodium chloride 0.9% is the intravenous diluent.

The DUPLEX container stores the drug and diluent in separate chambers until activation. This format reduces bedside preparation and can lower compounding requirements compared with conventional powder vials that require reconstitution and dilution.

Typical presentations include:

Product characteristic	Market relevance
Active ingredients	Piperacillin sodium and tazobactam sodium
Diluent	0.9% sodium chloride
Route	Intravenous infusion
Common strengths	3.375 g and 4.5 g total drug product, depending on presentation
Container	Dual-chamber flexible DUPLEX container
Primary customers	Hospitals, integrated delivery networks, government facilities and wholesalers
Therapeutic category	Broad-spectrum hospital antibacterial
Main substitutes	Generic piperacillin/tazobactam vials, premixed bags and alternative broad-spectrum antibiotics
Regulatory pathway	Abbreviated New Drug Application or legacy NDA-linked generic pathway

The product is used for intra-abdominal infections, hospital-acquired pneumonia, complicated skin and skin-structure infections, pelvic infections and other serious infections caused by susceptible organisms. Its use is subject to antimicrobial stewardship, renal-dose adjustment and local resistance patterns. [1]

What is the FDA regulatory status of the product?

Piperacillin and tazobactam injection is an FDA-approved prescription antibacterial. The original branded product, Zosyn, was developed by Lederle Laboratories, later associated with Wyeth and Pfizer. Generic versions entered the U.S. market after the underlying branded exclusivity and principal patent barriers expired.

The DUPLEX presentation is a finished dosage form rather than a new active pharmaceutical ingredient. Its regulatory value comes from formulation, container design, stability, manufacturing controls and ease of use.

The FDA label identifies the product as a sterile intravenous preparation requiring controlled storage, handling and administration. The applicable approval may vary by manufacturer, strength and container presentation. [1]

Does the product have FDA new-drug exclusivity?

No meaningful current new-drug exclusivity protects the active ingredients. Piperacillin/tazobactam has been available as a generic hospital antibiotic for many years.

The original product’s exclusivity period ended long before the current commercial market. Any commercial protection now depends mainly on manufacturing know-how, customer contracts, product quality, supply capacity and container technology.

What patents protect piperacillin and tazobactam in a DUPLEX container?

The core composition and therapeutic use are no longer protected by commercially significant United States patents. The principal patent estate for the piperacillin/tazobactam combination expired before the current generic market matured.

Potentially relevant rights fall into four groups:

1. Active-ingredient and combination patents.
2. Formulation and stability patents.
3. Container and delivery-system patents.
4. Manufacturing-process and packaging rights.

The first category has no material current exclusivity value for the marketed product. Container patents can have greater relevance because the DUPLEX system involves a proprietary dual-chamber architecture, activation mechanism and sterile packaging process. Those rights generally protect the delivery platform or manufacturing system rather than piperacillin/tazobactam as a molecule.

What is the Orange Book status of piperacillin and tazobactam?

The Orange Book lists patents and exclusivity associated with approved drug products, but it does not create a market monopoly for every generic presentation. Generic manufacturers typically rely on the reference product’s expired patent and exclusivity framework when filing ANDAs.

For this mature antibiotic, the key commercial conclusion is that the active product is off-patent. A manufacturer using a particular container system may still face contractual, technical or platform-IP constraints, but those constraints are different from Orange Book exclusivity.

No material current Paragraph IV litigation is broadly associated with the mature piperacillin/tazobactam market. Paragraph IV disputes were more relevant when generic applicants first challenged the branded product’s remaining listed patents.

When did piperacillin and tazobactam lose exclusivity?

The combination lost practical branded exclusivity in the early generic era. Generic piperacillin/tazobactam products have been marketed for more than a decade, and the U.S. market now has multiple manufacturers and presentations.

The relevant timeline is:

Period	Market event
1980s	Development and patenting of piperacillin/tazobactam technology
Early 1990s	FDA approval and commercial launch of Zosyn
2000s	Expiration of core patent and branded market protections
2000s-2010s	Expansion of generic vial and premixed presentations
2010s-present	Competition shifts to hospital contracts, supply reliability and presentation
Current market	Mature generic injectable with limited molecule-level pricing power

Exact patent expiration dates depend on the patent family, terminal disclaimers and jurisdiction. The core combination rights are expired for commercial purposes. [2][3]

What formulations are protected by the DUPLEX container?

The product’s strongest differentiator is the dual-chamber delivery format. A DUPLEX container can separate the drug from the sodium chloride diluent until administration. This design supports longer shelf-life management and reduces the number of manual preparation steps.

Formulation and packaging value can include:

• Premixed dose presentation.
• Reduced pharmacy compounding labor.
• Lower risk of preparation errors.
• Standardized concentration and infusion volume.
• Compatibility with hospital inventory systems.
• Reduced need to stock separate diluent bags.
• Potentially improved workflow during high-volume antibiotic administration.

These benefits do not create broad molecule-level exclusivity. They can support a price premium over conventional vials if a hospital values labor savings, lower preparation burden or better supply predictability.

The commercial strength of the formulation depends on stability data, storage requirements, container integrity, extractables and leachables testing, sterility assurance and compatibility with infusion equipment. The product remains exposed to substitution by generic vials when hospitals prioritize acquisition cost over pharmacy efficiency.

How strong is the patent estate for the product?

The active-ingredient patent estate is weak because the core composition is expired. The container and manufacturing estate can be more relevant, but its scope is narrower.

Protection category	Current strength	Commercial effect
Piperacillin composition	Low	No meaningful exclusivity
Tazobactam composition	Low	No meaningful exclusivity
Combination therapy	Low	Generic substitution permitted
Method of use	Low	Broad clinical uses are mature
Premixed formulation	Moderate to low	May support product-specific differentiation
Dual-chamber container	Moderate, depending on patent family	Can limit direct copying of the platform
Manufacturing process	Moderate	Can raise technical barriers without blocking all substitutes
Regulatory exclusivity	None of material commercial duration	Market remains generic

A competitor does not need to copy the DUPLEX system to compete. It can sell a vial-based product, a conventional premix or a different dual-chamber presentation. This limits the ability of container patents to produce durable market exclusivity.

Which companies compete with piperacillin and tazobactam DUPLEX products?

Competition comes from three groups:

Generic piperacillin/tazobactam manufacturers

Generic injectable manufacturers and hospital suppliers compete through ANDA-approved vials, premixed bags and institutional contracts. The field can include companies such as Sandoz, Hikma, Fresenius Kabi, Pfizer, Eugia, Aurobindo and other approved suppliers, depending on product availability and the specific strength.

The supplier mix changes frequently because of manufacturing transfers, shortages, discontinuations and procurement awards.

Premixed intravenous antibiotic suppliers

Premixed products from Baxter, B. Braun and other hospital-injection suppliers compete on convenience, pharmacy labor and delivery reliability. The DUPLEX system competes with ready-to-use bags and other dual-chamber technologies.

Therapeutic substitutes

Hospitals can substitute other broad-spectrum agents when clinically appropriate. Relevant alternatives include cefepime, meropenem, imipenem/cilastatin, ceftriaxone, ceftazidime and combinations involving metronidazole or vancomycin.

Therapeutic substitution is constrained by infection site, microbiology, renal function, resistance, formulary policy and antimicrobial stewardship. It is therefore a commercial risk, but not a simple one-for-one generic substitution.

What is the financial trajectory of the product?

Product-level revenue is not publicly reported for the DUPLEX presentation. B. Braun is privately held, and public disclosures generally do not isolate revenue for a single generic injectable SKU.

The likely financial trajectory has four stages:

Stage	Revenue and margin profile
Branded launch	High price and stronger gross margin
Early generic entry	Rapid volume growth and substantial price erosion
Mature generic market	Stable clinical demand, low unit pricing and contract-driven margins
Supply-constrained periods	Temporary price improvement, but higher manufacturing and compliance costs

The product benefits from recurring hospital demand because piperacillin/tazobactam is a standard empiric therapy in many institutions. Demand is less sensitive to consumer economic cycles than retail medicines. Volume can rise during periods of increased hospitalization, intensive-care utilization or bacterial infection burden.

Margins remain pressured by:

• Group purchasing organization contracts.
• Competitive hospital tenders.
• Multiple approved suppliers.
• Government pricing requirements.
• Raw-material and sterile manufacturing costs.
• Quality-control and compliance expenses.
• Product loss caused by short dating or inventory imbalance.
• Hospital substitution toward lower-cost vial formats.

The DUPLEX presentation may preserve a price premium where hospitals calculate total pharmacy labor rather than acquisition cost alone. That premium is vulnerable when purchasers experience budget pressure or when competing premixed products become available.

How do shortages affect market value?

Sterile injectable antibiotics are exposed to supply disruption because production requires specialized facilities, validated aseptic processes and constrained active pharmaceutical ingredient capacity. A manufacturing interruption can remove several suppliers at once if they rely on common raw-material sources or contract manufacturing networks.

FDA drug-shortage records have historically included injectable antibacterial products, including piperacillin/tazobactam presentations. Shortage conditions can increase short-term demand for available suppliers and strengthen contract renewals. They can also reduce profitability through expedited freight, allocation management, emergency production and regulatory remediation. [4]

A reliable supplier may gain account share even without patent protection. Hospitals often favor a vendor that can maintain fill rates across multiple strengths and package configurations.

What generic launch risks exist?

Generic launch risk is moderate for molecule access and higher for sterile manufacturing execution.

A new entrant faces:

• ANDA approval requirements.
• Demonstration of pharmaceutical equivalence and bioequivalence where applicable.
• Sterility and container-closure validation.
• Stability requirements for the finished product.
• Specialized dual-chamber packaging capability if it seeks to copy the presentation.
• Hospital contracting barriers.
• Distributor and wholesaler qualification.
• Competitive pricing from established suppliers.

A new entrant can avoid direct DUPLEX-platform competition by launching a vial. That reduces packaging barriers but also eliminates the convenience-based differentiation that can support higher net pricing.

What patent litigation and settlement agreements affect the product?

No major active patent litigation or settlement agreement is broadly associated with the current mature piperacillin/tazobactam market. The principal litigation risk occurred during generic entry against the branded reference product.

Current disputes are more likely to involve:

• ANDA manufacturing claims.
• Trade-secret allegations.
• Container or packaging patents.
• Contract disputes.
• Product liability.
• FDA manufacturing observations.
• Antitrust or supply-allocation issues.

These risks are distinct from a branded patent cliff. They can affect a specific supplier without preventing generic competition across the therapeutic category.

Is there biosimilar risk for piperacillin and tazobactam?

No. Biosimilar competition does not apply because piperacillin/tazobactam is a chemically synthesized small-molecule antibiotic, not a biological product.

The relevant competitive risk is generic injectable substitution. FDA ANDA competition can reach the same therapeutic market without the biologics licensing pathway used for biosimilars.

How does the DUPLEX product compare with standard generic vials?

Factor	DUPLEX container	Standard vial
Pharmacy preparation	Low	Higher
Container convenience	High	Low to moderate
Acquisition cost	Usually higher than vial equivalent	Usually lower
Inventory components	Combined drug and diluent system	Separate components may be required
Labor savings	Potentially meaningful	Limited
Copying barriers	Higher because of packaging technology	Lower
Hospital substitution risk	Moderate	High
Supply-chain value	Strong during labor or shortage pressure	Strong where cost dominates

The DUPLEX product is best positioned in hospitals that value ready-to-administer workflow and consistent supply. It is less advantaged in tenders based almost entirely on lowest acquisition price.

What is the geographic coverage of the product?

The commercial opportunity is strongest in the United States hospital market, where the FDA-approved product, group purchasing organizations and integrated delivery networks shape access.

International markets use piperacillin/tazobactam widely, but the exact container, labeling, supplier and regulatory status vary by jurisdiction. European, Canadian, Asia-Pacific and Latin American markets may rely on conventional vials, standard premixed bags or locally approved dual-chamber systems.

Geographic expansion requires country-specific registration, pharmacopoeial compliance, local packaging, public tender access and distribution infrastructure. The DUPLEX platform can support international differentiation, but it does not automatically transfer U.S. market authorization or hospital contracts to other markets.

Key Takeaways

• Piperacillin and tazobactam in sodium chloride in a DUPLEX container is a mature generic hospital injectable.
• Core molecule and combination patents no longer provide meaningful commercial exclusivity.
• The principal differentiator is the dual-chamber container and reduced pharmacy preparation burden.
• Revenue is not separately disclosed, so financial performance must be inferred from hospital injectable demand, contracting and supply conditions.
• Pricing is constrained by generic competition, group purchasing organizations and vial-based substitutes.
• Supply reliability can produce temporary share gains and pricing benefits during shortages.
• Biosimilar risk is not relevant; generic injectable competition is the primary threat.
• Container, manufacturing and sterile-processing IP may create narrower barriers, but they do not prevent therapeutic substitution.
• Long-term returns are likely to depend on manufacturing efficiency, contract retention, fill rates and the ability to justify a convenience premium.

Frequently Asked Questions

Is piperacillin and tazobactam in a DUPLEX container a branded drug?

It is a generic hospital injectable presentation associated with the DUPLEX dual-chamber delivery system. The active ingredients are off-patent.

Does the DUPLEX container justify a higher price than a vial?

It can justify a higher net price when hospitals value reduced compounding labor, standardized preparation and supply convenience. The premium is limited by vial-based generic competition.

Can a competitor launch piperacillin/tazobactam without using the DUPLEX system?

Yes. A competitor can market an approved vial or another premixed presentation without duplicating the DUPLEX container.

Is the product exposed to antimicrobial stewardship restrictions?

Yes. Hospitals increasingly restrict broad-spectrum antibiotic use through formulary controls, infectious-disease review and dose optimization. These controls can limit volume growth even when infection demand remains stable.

What is the main investment risk for this product?

The primary risk is margin compression combined with sterile-injectable supply disruption. Patent expiration is no longer the central risk because the molecule is already generic.

References

1. U.S. Food and Drug Administration. (2023). Piperacillin and tazobactam injection prescribing information. FDA/DailyMed.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA, Center for Drug Evaluation and Research.

3. U.S. Patent and Trademark Office. (2024). Patent Center and patent term information. U.S. Department of Commerce.

4. U.S. Food and Drug Administration. (2024). Drug shortages: Piperacillin and tazobactam injection. FDA Drug Shortages Database.